AMPHASTAR PHARMACEUTICALS ($NASDAQ:AMPH) reported their earnings results for the second quarter of FY2023 on June 30 2023. Revenue was USD 145.7 million, an 18.0% rise compared to the same quarter in the preceding year, and net income increased by 50.5%, amounting to USD 26.1 million.
The company’s stock opened at $63.3 and closed at $65.0, up by 3.0% from the previous closing price of 63.1. The company’s performance was fueled by increased demand for its generic drugs, as well as the success of its research and development program. AMPHASTAR PHARMACEUTICALS‘ sales included higher-than-expected sales from its drugs used to treat diabetes, rheumatoid arthritis, and multiple sclerosis. Moreover, the company’s investments into research and development allowed it to introduce new therapies and treatments that further augmented its sales figures. Looking ahead, AMPHASTAR PHARMACEUTICALS is optimistic about its prospects in the coming quarters.
The company expects to maintain its strong performance and continue to grow its market share in the generic drug market. The company is also looking to capitalize on its innovative research and development program to create new treatments that can help improve healthcare access around the world. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Amphastar Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Amphastar Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Amphastar Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Amphastar Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Amphastar Pharmaceuticals Intrinsic Value
At GoodWhale, we recently conducted an analysis of AMPHASTAR PHARMACEUTICALS’s wellbeing. Using our proprietary Valuation Line, we calculated the intrinsic value of AMPHASTAR PHARMACEUTICALS’s share to be around $32.6. However, the stock is currently being traded at $65.0, meaning it is overvalued by a whopping 99.7%. This offers investors a great opportunity to buy into the company at an incredibly discounted rate. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Amphastar Pharmaceuticals Inc and its competitors Mallinckrodt PLC, Avadel Pharmaceuticals PLC, RPG Life Sciences Ltd is fierce. All four companies are constantly trying to one-up each other in the race to create new and innovative drugs. This competition is good for the consumer, as it drives down prices and forces the companies to be constantly innovating.
Avadel Pharmaceuticals PLC is a pharmaceutical company with a market capitalization of 356.22 million as of 2022. The company’s return on equity is -255.63%. Avadel Pharmaceuticals PLC is engaged in the development, manufacture, and commercialization of pharmaceutical products. The company’s products include drugs for the treatment of sleep disorders, urinary incontinence, and attention deficit hyperactivity disorder.
– Avadel Pharmaceuticals PLC ($BSE:532983)
Life sciences is the study of living organisms, including plants, animals, and human beings. The company’s market cap is 14.42B as of 2022, a Return on Equity of 19.69%. The company focuses on the research and development of new drugs and therapies to treat diseases.
AMPHASTAR PHARMACEUTICALS reported strong financial performance for the second quarter of FY2023. Revenue grew 18% year-over-year to USD 145.7 million, and net income increased 50.5% to USD 26.1 million. This performance was reflected in the stock price, which rose on the news.
Investors interested in AMPHASTAR PHARMACEUTICALS should consider the company’s strong growth potential and focus on their financials. It is important to note that the stock may be volatile, so investors should exercise caution when investing in this company.